[go: up one dir, main page]

WO2002055064A3 - Traitement des mucopolysaccharidoses - Google Patents

Traitement des mucopolysaccharidoses Download PDF

Info

Publication number
WO2002055064A3
WO2002055064A3 PCT/US2002/000813 US0200813W WO02055064A3 WO 2002055064 A3 WO2002055064 A3 WO 2002055064A3 US 0200813 W US0200813 W US 0200813W WO 02055064 A3 WO02055064 A3 WO 02055064A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucopolysaccharidosis
therapies
inhibitors
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000813
Other languages
English (en)
Other versions
WO2002055064A2 (fr
Inventor
Steven Walkley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0100889.5A external-priority patent/GB0100889D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Priority to AU2002241853A priority Critical patent/AU2002241853A1/en
Publication of WO2002055064A2 publication Critical patent/WO2002055064A2/fr
Publication of WO2002055064A3 publication Critical patent/WO2002055064A3/fr
Anticipated expiration legal-status Critical
Priority to US10/619,378 priority patent/US20050032841A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de synthèse de glycosylcéramides dans le traitement des mucopolysaccharidoses.
PCT/US2002/000813 1999-04-20 2002-01-11 Traitement des mucopolysaccharidoses Ceased WO2002055064A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002241853A AU2002241853A1 (en) 2001-01-12 2002-01-11 Mucopolysaccharidosis therapies
US10/619,378 US20050032841A1 (en) 1999-04-20 2003-07-14 Therapeutic compositions and methods of treating glycolipid storage related disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0100889.5 2001-01-12
GBGB0100889.5A GB0100889D0 (en) 2001-01-12 2001-01-12 Compounds
US34723302P 2002-01-10 2002-01-10
US60/347,233 2002-01-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/619,378 Continuation US20050032841A1 (en) 1999-04-20 2003-07-14 Therapeutic compositions and methods of treating glycolipid storage related disorders

Publications (2)

Publication Number Publication Date
WO2002055064A2 WO2002055064A2 (fr) 2002-07-18
WO2002055064A3 true WO2002055064A3 (fr) 2002-09-26

Family

ID=26245554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000813 Ceased WO2002055064A2 (fr) 1999-04-20 2002-01-11 Traitement des mucopolysaccharidoses

Country Status (2)

Country Link
AU (1) AU2002241853A1 (fr)
WO (1) WO2002055064A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200007808A1 (it) 2022-04-20 2023-10-20 Luigi Michele Pavone Composizioni terapeutiche per malattie causate da accumulo di eparan solfato

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062779A1 (fr) * 1999-04-20 2000-10-26 Oxford Glycosciences (Uk) Limited Combinaison d'inhibiteurs de synthese de glucosylceramide et d'enzyme degradant les glycolipides utilisee en therapie
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062779A1 (fr) * 1999-04-20 2000-10-26 Oxford Glycosciences (Uk) Limited Combinaison d'inhibiteurs de synthese de glucosylceramide et d'enzyme degradant les glycolipides utilisee en therapie
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLATT F M ET AL: "N-BUTYLDEOXYNOJIRIMYCIN IS A NOVEL INHIBITOR OF GLYCOLIPID BIOSYNTHESIS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 269, no. 11, 18 March 1994 (1994-03-18), pages 8362 - 8365, XP000615445, ISSN: 0021-9258 *
PLATT F M ET AL: "NEW THERAPEUTIC PROSPECTS FOR THE GLYCOSPHINGOLIPID LYSOSOMAL STORAGE DISEASES", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 56, no. 4, 1998, pages 421 - 430, XP000886851, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2002055064A2 (fr) 2002-07-18
AU2002241853A1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002352443A1 (en) Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
WO2006015263A3 (fr) Analogues de lonidamine
WO2004089296A3 (fr) Inhibiteurs ameliores pour hydrolase epoxyde soluble
ZA200203123B (en) Therapeutic use of selective PDE10 inhibitors.
AU2003300791A1 (en) Combination therapy for the treatment of pain
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
WO2003088748A8 (fr) Utilisation d'heme-oxygenase-1 et produits de degradation d'heme
AU2001288101A1 (en) Ultrasonic beauty treatment probe
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
WO2002039997A3 (fr) Composes modulant ace-2 et procedes d'utilisation associes
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2003259246A1 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AUPQ866500A0 (en) Therapeutic compounds and methods
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP